Concepedia

Harry Haber

HH

23

Publications

2.8K

Citations

18

H-Index

1995

Active since

Affiliations

Eli Lilly (United States)(Current)

University of Michigan

University of Florida

University of British Columbia

Dalhousie University

Harry Haber is an author at Eli Lilly (United States) specializing in medicine, cardiovascular disease, and pharmacology.

Top concepts

Publications per year

1995–2020

23

Publications

23

Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease

G.B. John Mancini, Gregory C. Henry, Carlos Macaya et al. · Circulation · 1996 · 1.1K citations

Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor

J.W. Nawrocki, Stuart Weiss, Michael H. Davidson et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1995 · 484 citations

Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)

Todd J. Anderson, Eleanor Elstein, Harry Haber et al. · Journal of the American College of Cardiology · 2000 · 362 citations

, , +10

The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function

Bertram Pitt, Blair J. O’Neill, Robert Feldman et al. · The American Journal of Cardiology · 2001 · 228 citations

, , +9

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks

Michaëla Diamant, Luc Van Gaal, Stephen Stranks et al. · Diabetes Care · 2012 · 96 citations · Full text

Rows per page

1–5 of 23